Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy.


Journal

Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146

Informations de publication

Date de publication:
12 2022
Historique:
revised: 16 08 2022
received: 16 03 2022
accepted: 27 08 2022
pubmed: 12 10 2022
medline: 22 11 2022
entrez: 11 10 2022
Statut: ppublish

Résumé

We hypothesized that early, pretreatment axonal loss would predict long-term disability, supported by a pilot study of selected patients with chronic inflammatory demyelinating polyneuropathy (CIDP). To further test this hypothesis, we examined a larger consecutive group of CIDP patients. Needle electromyography and motor and sensory nerve conduction studies were carried out in 30 CIDP patients at pretreatment and follow-up 5 to 28 years later. Changes in amplitudes were expressed as axonal Z scores and changes in conduction as demyelination Z scores and correlated with findings of the Inflammatory Rasch-built Overall Disability Scale (I-RODS), the Neuropathy Impairment Score (NIS), and isokinetic dynamometry (IKS). At follow-up, the median I-RODS score was 73, the NIS was 23, and the IKS was 56%. The median axonal Z score was unchanged at follow-up. Conversely, the corresponding demyelination Z scores improved. The initial axonal loss was correlated with the clinical outcome and was an independent predictor of outcome by multivariate regression analysis. Axonal loss at follow-up was also correlated with the clinical outcome. Only the follow-up demyelination Z score was correlated with the clinical outcomes. Furthermore, the latency until treatment initiation was predictive of all three clinical outcome scores at follow-up, and of axonal loss and demyelination at follow-up. The present study findings indicate that pretreatment axonal loss at diagnosis in CIDP is predictive of long-term disability, neurological impairment, and strength. A delay in treatment is associated with more pronounced axonal loss and a worse clinical outcome.

Identifiants

pubmed: 36217677
doi: 10.1002/mus.27722
pmc: PMC9828077
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

715-722

Informations de copyright

© 2022 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.

Références

Muscle Nerve. 2020 Mar;61(3):316-324
pubmed: 31793666
Muscle Nerve. 2016 Jun;53(6):889-96
pubmed: 26479267
Muscle Nerve. 1992 Mar;15(3):374-83
pubmed: 1557087
J Peripher Nerv Syst. 2008 Sep;13(3):208-17
pubmed: 18844787
Eur J Appl Physiol. 2012 Jan;112(1):267-75
pubmed: 21537927
Brain. 1996 Feb;119 ( Pt 1):257-70
pubmed: 8624687
Brain. 1987 Dec;110 ( Pt 6):1617-30
pubmed: 3427403
Neurology. 1997 Jul;49(1):229-39
pubmed: 9222195
Eur J Neurol. 2019 Aug;26(8):1121-1129
pubmed: 30882969
J Neurol. 2017 Sep;264(9):1939-1944
pubmed: 28770373
Clin Neurophysiol. 2019 Aug;130(8):1280-1288
pubmed: 31163374
J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):973-85
pubmed: 25677463
Neuromuscul Disord. 2006 May;16(5):293-303
pubmed: 16631367
Neurology. 1999 Feb;52(3):498-503
pubmed: 10025777
Exp Neurol. 2012 Jun;235(2):513-6
pubmed: 22507308
J Neurol Sci. 1976 Apr;27(4):427-58
pubmed: 1262904
Muscle Nerve. 2008 Aug;38(2):1036-45
pubmed: 18642356
Neurology. 2014 Mar 11;82(10):879-86
pubmed: 24523485
Clin Neurophysiol. 2021 Apr;132(4):1000-1007
pubmed: 33581994
Clin Neurophysiol. 2016 Jan;127(1):898-904
pubmed: 26049677
Curr Opin Neurol. 2016 Jun;29(3):213-21
pubmed: 27058223
Neurology. 1981 Apr;31(4):413-21
pubmed: 7194432
Eur J Neurol. 2021 Nov;28(11):3556-3583
pubmed: 34327760
IEEE Trans Biomed Eng. 2011 Oct;58(10):2707-18
pubmed: 20699205
J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):66-70
pubmed: 16361595
Neurol Sci. 2000 Feb;21(1):31-7
pubmed: 10938200
N Engl J Med. 2005 Mar 31;352(13):1343-56
pubmed: 15800230
Brain. 2021 May 7;144(4):1043-1045
pubmed: 33962470
Neurology. 2011 Jan 25;76(4):337-45
pubmed: 21263135
Neurology. 2005 Apr 26;64(8):1471-5
pubmed: 15851750
Clin Neurophysiol. 2017 Oct;128(10):2022-2028
pubmed: 28837908
Muscle Nerve. 2018 May;57(5):848-851
pubmed: 29130507
Muscle Nerve. 2022 Dec;66(6):715-722
pubmed: 36217677
PLoS One. 2011 Jan 18;6(1):e14533
pubmed: 21267074
J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):727-33
pubmed: 10329744
Curr Opin Neurol. 2017 Oct;30(5):508-512
pubmed: 28763304

Auteurs

Ali Al-Zuhairy (A)

Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Johannes Jakobsen (J)

Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Mihai Moldovan (M)

Department of Clinical Neurophysiology, Rigshospitalet and Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.

Christian Krarup (C)

Department of Clinical Neurophysiology, Rigshospitalet and Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH